How does schizophrenia differ between men and women? And are there adjunctive treatments that can improve outcomes for female patients with schizophrenia?

Aducanumab (Aduhelm) just got FDA approval in dementia, but many experts think it should not have passed the finish line. We interviewed Peter Whitehouse, professor of neurology at Case Western Reserve University and author of American Dementia, on what went wrong.

Patients with repeated deliberate foreign body ingestion (DFBI) are among the most challenging we see. In any given room, there’s bound to be some small object that can be swallowed. So how can we reduce the likelihood of foreign body ingestion in these patients?

Clinicians explore what to do if your patient just has mania and doesn’t tend to have much trouble with depression.

What distinguishes Kloxxado from the many other ways naloxone is delivered and why was it developed in the first place?

In the final episode of our 3-part series on antipsychotics, you’re going to find out whether these drugs have a class effect in mania, among other topics that inform practice.

We break down three main autism intervention approaches, and provide you with information that will help you improve on your abilities to recognize which particular autism intervention might be best for a specific patient.

A review of how an anesthetic agent turned into an antipsychotic, and how Bing Crosby lit a spark that would eventually lead psychiatrists to revise their entire diagnostic system.

An interview with Michael Poyurovsky, MD, on the paradoxical effects of antipsychotics in OCD and the many ways that OCD symptoms show up in schizophrenia.

Genetic testing is all the rage in psychiatry, but the test that might work best is the one that no one is talking about.